Application of Patient Blood Management in the Oncology Patient Affected by Breast Cancer
ConditionBreast Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorRegina Elena Cancer Institute
About this trial
Evaluation of the percentage of transfusions in patients with breast cancer undergoing surgery after preventive treatment with haematinics.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age > 18 years;
patients diagnosed with histologically confirmed breast cancer and whether or not they have undergone neoadjuvant chemotherapy;
patients who are candidates for destructive and reconstructive breast surgery or not;
Hb values less than or equal to 11 g/dL and/or transferrin saturation less than or equal to 20%;
Disqualifiers
patients with known allergies to ferric carboxymaltose or its excipients;
ferritin values greater than 500 ng/ml;
patients unable to sign consent and comply with procedures.
Trial population
Patients with breast cancer who have undergone or not undergone neoadjuvant chemotherapy and with Hb values lower than or equal to 11 g/dl, candidates for destructive and/or reconstructive surgery.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
78 Participants
are grouped into 1 trial groupGroup A: Patients with breast cancer who have received neoadjuvant chemotherapy or not
Trial outcomes
Primary outcomes
1
Number of transfusions
To evaluate the percentage, in number of transfusions in patients affected by breast cancer, candidates for destructive and/or reconstructive breast surgery after preventive treatment with haematinics
Time frame
18 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Regina Elena Cancer Institute
Lead sponsor
Campus Bio-Medico University
Collaborator
Umberto I Hospital, Frosinone Italy
Collaborator
Source ClinicalTrials.gov